Who are Angiotensin receptor blocker's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): The RP group, The DR group, A3, MIR, angiotensin blockade, Stop group.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/angiotensin-receptor-blocker.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Angiotensin receptor blocker — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Angiotensin receptor blocker (Angiotensin receptor blocker) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin receptor blocker. Area: Cardiovascular.

marketed Angiotensin receptor blocker AT1 receptor (Angiotensin II type 1 receptor) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Angiotensin receptor blocker (Angiotensin receptor blocker) — National University of Ireland, Galway, Ireland. Angiotensin receptor blockers block the angiotensin II type 1 receptor, preventing vasoconstriction and aldosterone release to lower blood pressure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Angiotensin receptor blocker TARGET	Angiotensin receptor blocker	National University of Ireland, Galway, Ireland	marketed	Angiotensin receptor blocker	AT1 receptor (Angiotensin II type 1 receptor)
The RP group	The RP group	Beijing Tiantan Hospital	marketed	Angiotensin receptor blockers (ARBs)	AT1 receptor
The DR group	The DR group	Beijing Tiantan Hospital	marketed	Angiotensin receptor blocker (ARB)	AT1 receptor
A3	A3	Breath of Life International Pharma Ltd	marketed	Angiotensin receptor blocker	AT1 receptor
MIR	MIR	Rambam Health Care Campus	marketed	Angiotensin receptor blocker	AT1 receptor
angiotensin blockade	angiotensin blockade	The University of Hong Kong	marketed	Angiotensin receptor blocker (ARB) or ACE inhibitor	Angiotensin II type 1 receptor (AT1R) or Angiotensin-converting enzyme (ACE)
Stop group	Stop group	Asan Medical Center	marketed	Angiotensin receptor blocker	AT1 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiotensin receptor blocker class)

Asan Medical Center · 1 drug in this class
Breath of Life International Pharma Ltd · 1 drug in this class
National University of Ireland, Galway, Ireland · 1 drug in this class
Rambam Health Care Campus · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Angiotensin receptor blocker — Competitive Intelligence Brief. https://druglandscape.com/ci/angiotensin-receptor-blocker. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab